Agenus to Participate in the Raymond James 2021 Human Health Innovation Conference
June 21, 2021 09:00 ET
|
Agenus Inc.
LEXINGTON, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer
June 17, 2021 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies,...
Agenus Announces Virtual Annual Shareholders Meeting
June 15, 2021 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Agenus’ Presentations at ASCO 2021 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373
June 04, 2021 09:09 ET
|
Agenus Inc.
LEXINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Agenus to Participate in Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference
June 01, 2021 16:05 ET
|
Agenus Inc.
LEXINGTON, Mass., June 01, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts
May 20, 2021 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Agenus to Host Conference Call to Discuss Global Licensing Agreement with Bristol Myers Squibb for Agenus’ Anti-TIGIT Bispecific Antibody Program
May 18, 2021 07:31 ET
|
Agenus Inc.
LEXINGTON, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
May 18, 2021 07:30 ET
|
Agenus Inc.
NEW YORK and LEXINGTON, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Bristol-Myers Squibb Company (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive...
Agenus Corporate Update and First Quarter 2021 Financial Report
May 06, 2021 07:45 ET
|
Agenus Inc.
Balstilimab BLA submitted to FDA for recurrent/metastatic cervical cancerBalstilimab and AGEN2373 data to be presented at ASCOiNKT cell therapy Phase 1 initiated in cancer LEXINGTON, Mass., May 06,...
Agenus to Present at the 2021 ASCO Annual Meeting
April 28, 2021 17:30 ET
|
Agenus Inc.
LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...